- Allied Interventions in HIV/AIDS
- Antiretroviral Management in Adults and Adolescents
- Antiretroviral Management in Pediatrics
- Epidemiology
- HIV Resistance
- HIV Testing
- HIV and Aging
- Management of HIV in Key Populations
- Management of Non-infectious Comorbidities in HIV
- Opportunistic Infections and Coinfections
- Post-exposure prophylaxis (PEP)
- Pre-exposure Prophylaxis (PrEP)
- Preventing Mother to Child Transmission
- Primary Care in HIV
- Treatment as Prevention (TasP)
Webcasts
Our Publications
Key Trials
- 48-week Efficacy and Safety of Switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide in Virologically Suppressed People Living with HIV aged > 65 years
- Efficacy of Reduced Doses of both TDF and EFV for the Treatment of HIV-1 Infection
- 144-week Efficacy and Safety of Fixed-dose Combination Bictegravir, Emtricitabine, and Tenofovir alafenamide versus Dolutegravir-containing Regimens for Initial Treatment of HIV-1 Infection
- Long Acting Injectables (CAB+RPV) for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase III ATLAS and FLAIR Studies
- ADVANCE Trial: 96-week Efficacy and Safety of DTG Combined with FTC and TAF or TDF versus EFV Combined with FTC and TDF
- PRADAR Study: Virological Efficacy of Abacavir/Lamivudine + DRV/r vs Abacavir/ Lamivudine + RAL in Treatment -naïve HIV Patients with CD4<200 cells/μL
- Switching to FTC/TAF from FTC/TDF in Virologically Suppressed Patients receiving a Boosted PI or an Unboosted Third Agent
- ADVANCE Trial: DTG Combined with TAF or TDF, Noninferior to the Standard -of- care Regimen at Week 48
- TAF Based Regimen Superior to TDF–based Regimen in Efficacy and Renal and Bone Safety for Initial HIV-1 Treatment
- Safety and Efficacy of E/C/F/TAF vs E/C/F/TDF in Treatment Naïve HIV Patients
Guidelines
- Updated Recommendations on HIV Prevention, Infant Diagnosis, Antiretroviral Initiation and Monitoring (2021)
- IAS-USA: Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: Recommendations of the International Antiviral Society–USA Panel (2020)
- WHO: Update of Recommendations on First- And Second-Line Antiretroviral Regimens (2019)
- WHO: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection 2016- Recommendations for a Public Health Approach: second edition (2016)
- European AIDS Clinical Society (EACS): Guidelines for Treatment of HIV-infected Adults in Europe (2016)
- Southern African HIV Clinicians Society: Adult Antiretroviral Therapy Guidelines: Update on when to initiate antiretroviral therapy (2015)
- BHIVA: Guidelines for the Treatment of HIV-1-positive Adults with Antiretroviral Therapy (2015)
- Southern African HIV Clinicians Society: Guideline on Adult Antiretroviral Therapy Guidelines 2014
Our Publications
Clinical Tools
Guidelines
- Updated Recommendations on HIV Prevention, Infant Diagnosis, Antiretroviral Initiation and Monitoring (2021)
- DHHS: Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection (2020)
- PENTA: HIV First and Second Line Antiretroviral Treatment Guidelines (2019)
- WHO: Updated Recommendations On First-line and Second-line Antiretroviral Regimens and Post-exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidance (2018)
- WHO: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection 2016- Recommendations for a Public Health Approach: second edition (2016)
Our Publications
Clinical Tools
- Algorithm for Management of Osteopenia/Osteoporosis in HIV-Infected Patients
- eGFR Calculator
- Cockgroft Gault Equation
- MDRD GFR Calculator
- 10 year Risk for Coronary Heart Disease Framingham Point Scores
- 10-year Risk of Developing CHD (Myocardial Infarction and Coronary Death)
- Fracture Risk Assessment Tool
- 10 year Fracture Risk Calculator
Guidelines
- WHO: Integrating Collaborative TB and HIV Services Within a Comprehensive Package of Care for People who Inject Drugs (2016)
- Guideline on Management of Mental Health Disorders and Central Nervous System Sequelae in HIV-positive Children and Adolescents (2014)
- BHIVA: Guidelines for HIV-associated Malignancies (2014)
- Southern African HIV Clinicians Society: Guideline on Management of Mental Health Disorders in HIV-positive Patients (2014)
- Southern African HIV Clinicians Society: Guideline on Consensus statement: Management of Drug-induced Liver Injury in HIV-positive Patients Treated for TB (2013)
Our Publications
Key Trials
Guidelines
- BHIVA: Management of Tuberculosis in Adults Living with HIV (2021)
- DHHS: Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2020)
- DHHS: Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children ( 2019)
- Guidelines for the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children (2018)
- BHIVA: Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV (2013)
Our Publications
Guidelines
- Southern African HIV Clinicians Society: Guideline on the Management of Occupational and Non-Occupational Exposure to the Human Immunodeficiency Virus and recommendations for post-exposure prophylaxis: 2015 Update (2016)
- WHO: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection 2016- Recommendations for a Public Health Approach: second edition (2016)
- BHIVA:UK National Guideline for the Use of HIV Post-Exposure Prophylaxis Following Sexual Exposure (PEPSE) 2015
- CDC: Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States (2014)
- WHO: Guidelines on Post-exposure Prophylaxis for HIV and the Use of Co-trimoxazole Prophylaxis for HIV-related Infections among Adults, Adolescents and Children (2014)
- CDC: U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Post-exposure (2013)
Our Publications
Key Trials
- DISCOVER Study: Efficacy and Safety of F/TAF with F/TDF for the Prevention of HIV Among Cisgender MSM and Transgender Women Who Have Sex with Men
- Pre-exposure Chemoprophylaxis with Oral FTC–TDF Prevents HIV Acquisition in Men Who have Sex with Men
- Partners PrEP Study: Oral TDF or TDF–FTC Significantly Reduces the Risk of HIV-1 Acquisition among Heterosexual Men and Women in Serodiscordant Relationships
Guidelines
- WHO: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection 2016- Recommendations for a Public Health Approach: second edition (2016)
- Southern African HIV Clinicians Society: Guidelines on the Safe Use of Pre-exposure Prophylaxis in Persons at Risk of Acquiring HIV-1 Infection (2016)
- WHO: Guideline on When to Start Antiretroviral Therapy and on Pre-exposure Prophylaxis for HIV (2015)
- CDC: Pre-exposure Prophylaxis for the Prevention of HIV Infection – 2014 : A Clinical Practice Guideline (2014)